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Introduction
Dofetilide is one of the several novel
methanesulfonamide compounds that selectively
inhibits the rapid component of the delayed rectifier
potassium current, IKr, thus prolonging the effective
refractory period (ERP) and the action potential duration
(APD) in both the atria and the ventricles. It has no
effects on sodium and calcium channels, and therefore,
has minimal effects on myocardial conduction
velocity.1,2 Dofetilide can be administered either orally
or intravenously, and has a rapid onset of action. It was
recently approved in the United States for the
maintenance and conversion of normal sinus rhythm in
patients with atrial fibrillation (AF).3

Pharmacology
Dofetilide was selected for development from a
series of bis(arylalkyl)amines which prolonged ERP in
isolated cardiac tissue. A particularly advantageous
structural feature was a methanesulfonamido moiety on
both of the aryl rings. Dofetilide is a white crystalline
solid with a melting point of 161 degC and a molecular
weight of 441.6. The compound contains a tertiary
amine function with a pKa of 7.0 and is moderately
lipophilic.4
Dofetilide binds with high affinity to a population
of noninteracting sites, inhibiting the rapidly activating
component of the delayed rectifier potassium current
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(IKr) channel. The target IKr channel protein is encoded
by the human ether-a go-go-related gene (HERG).5
Dofetilide binds to the internal pore of the channel at a
site that involves the serine residue at position 620
(Ser620) and blocks IKr channels at 10 to 30 nM.6 At
these concentrations, it does not block IKs or the inward
rectifier IKi, nor does it affect sodium or calcium
currents. This yields a selective prolongation of action
potential and increases the refractory period. The
electrophysiological effect leads to QT interval
prolongation, which can be both antiarrhythmic and
proarrhythmic.7 On the other hand, dofetilide displays
little affinity for alpha 2 and beta adrenoceptors,
adenosine (A1), dopamine (D2), 5-HT2, muscarinic, or
opioid receptor or dihydropyridine binding sites, which
consequently has no other electrophysiological effects.
In contrast to other class III antiarrhythmic agents,
such as amiodarone or sotalol, dofetilide selectively
inhibits single channel, IKr, and widens APD. 8,9 It
prolongs the ERP in both atrial and ventricular tissues
in normal subjects, 10,11 as well as in acute ischemic
animals.12 Intravenous administration of dofetilide in
patients with ischemic heart disease also results in a
dose-dependent increase in monophasic APD and ERP
in the atria and ventricles.13,14 The associated QT interval
prolongation was closely related to the plasma
concentration of dofetilide after both iv and po
administration.15,16 Its maximal effect on QT duration
occurs 5 min after completion of iv infusion, or 2 ±
0.9 h post dosing po. There was an approximately 9
min lag between peak concentrations and peak effect
on the QT interval after infusion of dofetilide. 17
Dofetilide is typically rate dependent. The magnitude
of increases in APD or ERP decrease as the rate of
stimulation is increased.8,18 In vitro studies demonstrated
that using dofetilide at a slower heart rate and increased
intracellular Ca2+ would increase the risk of torsades
de pointes.19
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Dofetilide only prolongs repolarization by blocking the
open state of IKr, thus it have no effects on the PR or
RR, AH or HV intervals or QRS width or sinus node
recovery time.20 Dofetilide had a positive inotropic
effect not only in isolated heart muscles21 but also in
the atria in patients immediately following
cardioversion.22 It did not significantly affect the blood
pressure, heart rate or any other hemodynamic variables
in animal models, normal volunteers or patients with
acute ischemic heart failure.21,22 It only produced a slight
improvement in cardiac performance as demonstrated
by decreases in pulmonary capillary wedge pressure and
increases in left ventricular dP/dt.

Metabolism
Dofetilide is completely absorbed after oral
administration, and bioavailability ranges from 75 to
100% in subjects with normal renal function.23 Mean
maximal plasma concentration is reached approximately
2.5 h (range of 1 to 4 h) after oral administration and
the plasma half-life was 8 to 10 h (mean 9.5 h). 16
Approximately 50% of the drug is excreted in the urine
unchanged and the remaining 50% is metabolized in
the liver to inactive metabolites. The elimination halflife from plasma is 7 to 13 h (8.1 ± 2.3 h) and the
clearance is estimated to be 0.38 ± 0.05 l/h/kg during
oral administration. Corresponding values were similar
during iv administration (7.1 ± 1.3 h and 0.35± 0.05
l/h/kg, respectively). 17,19,24 Dofetilide is metabolized
predominantly by the CYP3A4 of the cytochrome-450
family.25 As a result, it may interact with drugs such as
erythromycin or ketoconazole, resulting in higher and
potentially toxic levels of dofetilide. Despite its hepatic
metabolism, dofetilide does not interact with digoxin,
propranolol, or warfarin. In both volunteers and patients,
drug clearance appeared to be independent of dose and
showed very little variability among patients.22,26,27 The
time to maximal plasma concentration was slightly
delayed in the presence of food, although the overall
absorption was not affected.

Clinical Use
An open dose-ranging study showed that 53% of
24 patients with AF were converted successfully to sinus
59

rhythm. The success rate was 80% in patients with atrial
flutter (AFL), but the number of patients in this study
was small. 28 In another study with 325 patients,
dofetilide (500 mg po bid for 3 days) converted chronic
AF/AFL to normal sinus rhythm safely and effectively
with a comparatively low conversion rate of 32%.29
Kobayashi et al evaluated the efficacy of iv dofetilide
in patients with paroxysmal AF of recent onset (< 7
days) and paroxysmal supraventricular tachycardia
(PSVT). Intravenous dofetilide successfully converted
AF to sinus rhythm in 7/13 (54%) at the dose of 2.5 to
5.0 µg/kg and prevented the induction of PSVT in 7/13
patients with a loading dose of 3 µg/kg followed by a
maintenance dose of 2 µg/kg.30
In a double-blind, randomized multicenter study
with dofetilide (4 or 8 µg/kg) or placebo, Falk et al
demonstrated that dofetilide terminated AF in 31% of
patients receiving 8 µg/kg and in 12.5% of those
receiving 4 µg/kg, compared with zero conversion after
placebo (p < 0.01). Meanwhile, dofetilide seemed to be
more effective in converting patients with AFL than
that with AF (14 versus 54%), though the number of
patients with AFL was small.31 Similarly, a multicenter,
randomized, double-blind, placebo-controlled trial of
demonstrated that dofetilide (8 µg/kg iv) was effective
in acute termination of AF of medium duration in 96
patients, with an efficacy rate as much as 2-fold higher
in AFL.32
The efficacy of dofetilide in patients with lifethreatening sustained ventricular tachycardia (VT) or
fibrillation (VF) was evaluated in a placebo-controlled
study using a dose-ranging protocol.33 24 Patients were
studied at six incremental loading and maintenance
infusion regimens. Sustained VT or VF was no longer
inducible in 1/6 patients receiving placebo and 8/18
patients receiving dofetilide. But compared to placebo,
dofetilide (0.1 to 8.0 ng/ml in plasma) produced
concentration-related increases in QT, QTc and right
ventricular ERP.
In a multicenter open trial, 34 the Dofetilide
Arrhythmia Study Group further evaluated the
electrophysiological effects, antiarrhythmic efficacy and
the safety of different doses of iv dofetilide in 50 patients
with sustained inducible monomorphic VT who had
previously been unsuccessfully treated with 0 to 7
(median 3) other drugs. Dofetilide was administered
over 60 min at doses of 1.5, 3, 6, 9 and 15 µg/kg iv.
Doses of 3 to 15 µg/kg prolonged the QTc interval by
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13.4 to 14.2%, the ventricular ERP by 7.9 to 20.6%
and the ventricular functional refractory period by
7.3 to 25%. The corresponding plasma dofetilide
concentrations ranged from 1.45 ± 0.52 to 6.48 ±
1.31 ng/ml. At these doses, iv dofetilide suppressed
or slowed inducible VT in 41% patients (17/41),
compared with 0/9 patients receiving the inactive dose
of 1.5 µg/kg. Furthermore, dofetilide prolonged the
interval to first all-cause implantable cardioverter
defibrillator (ICD) shocks, but not the interval to first
ICD intervention (antitachycardia pacing and or shock)
in 174 patients implanted with a ICD.35 Intravenous
dofetilide also reduced the amount of energy required
for converting VF to normal sinus rhythm by
approximately 2 to 3 J in patients with ICD.36
A total of 3000 patients with either acute
myocardial infarction or congestive heart failure (CHF)
requiring hospitalization were enrolled in the
DIAMOND (Danish Investigations of Arrhythmia and
Mortality on Dofetilide) trial, beginning in 1994.37 Of
these, 1518 patients with symptomatic CHF and severe
left ventricular dysfunction were recruited into the
randomized, double-blind DIAMOND-CHF trial. The
mortality rate was not significantly different between
the dofetilide and placebo group, but dofetilide was
effective in converting AF, preventing its recurrence
and reducing the risk of hospitalization for worsening
heart failure. Furthermore, dofetilide could be used
safely even in patients with severe forms of CHF for
AF, providing that the dose was carefully titrated
according to renal function, and treatment was initiated
with at least 72 h cardiac monitoring for development
of torsades de pointes.38 However, dofetilide was not
effective in acute termination of AF/AFL in patients
after coronary artery bypass surgery.39
The efficacy of dofetilide in converting AF/AFL
has been compared to other antiarrhythmic agents in
many studies. It may be more effective than flecainide
in the conversion of atrial flutter. 40 In multicenter,
randomized, double-blind, placebo-controlled studies,
intravenously administered dofetilide was found to
be more effective than amiodarone (35.4% vs. 4%,
p<0.0001) in the acute termination of AF and AFL with
short duration, 41 and also more effective than
procainamide (31% vs.12.7%, P<0.005) in the acute
conversion of AF/AFL with relative even of long
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duration.42 Double-blind randomized parallel group
study showed that dofetilide was at least equally
efficacious as propafenone in prevention of PSVT
attacks in patients waiting for radiofrequency ablation
therapy, and dofetilide was safer and better tolerated
than propafenone in terms of severity of events
reported.43 But, these studies were limited by the number
of patients recruited. Recently, results from the
supraventricular arrhythmia trial of 671 patients with
AFL/AF showed 29% of dofetilide treated patients
converted to normal sinus rhythm, versus 5% for sotalol
and 1% for placebo. Furthermore, 51% of patients
remained in normal sinus rhythm with dofetilide
compared to 38% with sotalol and 16% with placebo.44
The relative efficacy of dofetilide compared with other
conventional antiarrhythmic agents still need to be
confirmed by larger clinical trials.

Side-effects and Contraindications
Dofetilide is generally well tolerated. Non-cardiac
side effects reported infrequently included headache,
sinus tachycardia, and muscle cramps, which were mild
and transient.16 However, an animal study suggested that
short-term administration of dofetilide would reduce
the fluid secretion by rat testis and may cause
phagocytosed spermatids and atrophy of the testis.45
Whether fertility would be affected with long-term
treatment of dofetilide in human is not known yet. Like
other Class III drugs, the major concern is the risk of
torsades de pointes. The reported incidence of torsades
de pointes with dofetilide was 3-8.3 %,32,38 which was
less common than ibutilide and sotalol.46,47 The risk of
torsades de pointes is comparatively higher in patients
with structural heart disease. 32,41 A contraindication
should be the presence of prolonged QT interval before
drug administration. The dose of dofetilide should be
titrated carefully according to renal function and
initiated together with a minimum of 72 h of in-hospital
cardiac monitoring. Patients receiving dofetilide for the
maintenance of sinus rhythm should be closely
evaluated in the immediate post-cardioversion period
to detect excessive QT prolongation. Infusion of
dofetilide should be discontinued when significant
prolongation of QT interval in the ECG is observed.48
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Conclusion
Dofetilide selectively inhibits the rapid component
IKr of the delayed rectifier potassium current to prolong
the APD and ERP in the atrial and ventricular
myocardium. It targets only one cardiac ion channel
with no effects on the sinus node, cardiac conduction
system and other extracardiac organs. Dofetilide is a
promising compound for the treatment of lifethreatening ventricular arrhythmias as well as for
prevention of recurrent AF/AFL, and is currently
approved in the United States for the treatment of AF.
Intravenous dofetilide may represent a valuable
alternative to direct current cardioversion for acute
termination of AF/AFL. Furthermore, dofetilide does
not increase mortality in patients with clinically
significant structural heart disease and reduced left
ventricular function. Therefore, like amiodarone,
dofetilide can be used to prevent AF recurrence and
thus reduce the risk of hospitalization due to worsening
heart failure in patients with CHF.32 The clinical role of
dofetilide in the treatment of ventricular arrhythmias
requires further evaluation.
The major concern with the use of dofetilide is
the development of serious arrhythmias, in particular
torsades de pointes. The infusion of dofetilide should
be carefully adjusted and patients with atrial fibrillation
should be closely evaluated with in-hospital cardiac
monitoring during and after the cardioversion period to
avoid excessive QT prolongation.
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